Success Metrics

Clinical Success Rate
79.7%

Based on 263 completed trials

Completion Rate
80%(263/330)
Active Trials
213(28%)
Results Posted
39%(103 trials)
Terminated
67(9%)

Phase Distribution

Ph phase_1
126
17%
Ph phase_2
332
44%
Ph phase_4
9
1%
Ph early_phase_1
4
1%
Ph phase_3
129
17%
Ph not_applicable
84
11%

Phase Distribution

130

Early Stage

332

Mid Stage

138

Late Stage

Phase Distribution684 total trials
Early Phase 1First-in-human
4(0.6%)
Phase 1Safety & dosage
126(18.4%)
Phase 2Efficacy & side effects
332(48.5%)
Phase 3Large-scale testing
129(18.9%)
Phase 4Post-market surveillance
9(1.3%)
N/ANon-phased studies
84(12.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.5%

263 of 344 finished

Non-Completion Rate

23.5%

81 ended early

Currently Active

213

trials recruiting

Total Trials

757

all time

Status Distribution
Active(273)
Completed(263)
Terminated(81)
Other(140)

Detailed Status

Completed263
Recruiting156
unknown138
Terminated67
Not yet recruiting57
Active, not recruiting57

Development Timeline

Analytics

Development Status

Total Trials
757
Active
213
Success Rate
79.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (0.6%)
Phase 1126 (18.4%)
Phase 2332 (48.5%)
Phase 3129 (18.9%)
Phase 49 (1.3%)
N/A84 (12.3%)

Trials by Status

completed26335%
enrolling_by_invitation30%
recruiting15621%
terminated679%
suspended20%
unknown13818%
not_yet_recruiting578%
active_not_recruiting578%
withdrawn142%

Recent Activity

Clinical Trials (757)

Showing 20 of 757 trialsScroll for more
NCT03340896Phase 3

Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT

Active Not Recruiting
NCT05685004Phase 2

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Active Not Recruiting
NCT07498907Phase 3

Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

Recruiting
NCT04557059Phase 3

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

Active Not Recruiting
NCT04062708Phase 2

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Active Not Recruiting
NCT05109728Phase 1

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Active Not Recruiting
NCT05765812Phase 1

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Recruiting
NCT06582446Phase 2

Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)

Recruiting
NCT07177443Phase 3

Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma

Recruiting
NCT05043688Phase 3

Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.

Active Not Recruiting
NCT00421096Phase 2

Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer

Terminated
NCT07527884Not Applicable

The Effect of Radiotherapy After Separation Surgery for Spinal Metastases

Recruiting
NCT06459869Phase 1

NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

Active Not Recruiting
NCT07776080Phase 2

Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Recruiting
NCT05301881Phase 2

COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study

Recruiting
NCT07000253Phase 2

Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma

Recruiting
NCT07026474Phase 3

Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

Recruiting
NCT06390176Phase 2

Lactobacillus Rhamnosus GG Alleviates Oral Mucositis in Patients Undergoing Radiotherapy

Completed
NCT06934889Phase 1

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

Recruiting
NCT05929222Phase 3

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting

Drug Details

Intervention Type
RADIATION
Total Trials
757